Compile Data Set for Download or QSAR
maximum 50k data
Found 1333 with Last Name = 'mehrotra' and Initial = 'm'
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Portola Pharmaceuticals

US Patent
LigandPNGBDBM100350(US10533001, Example 99 | US11414410, Example 99 | ...)
Affinity DataIC50:  0.800nM Kd:  2.70nMAssay Description:ATP-site dependent competition binding assay using Ambit KinomeScan Screening kit.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Portola Pharmaceuticals

US Patent
LigandPNGBDBM100350(US10533001, Example 99 | US11414410, Example 99 | ...)
Affinity DataIC50:  0.800nMAssay Description:The kinase reaction is performed in a black U-bottom 96-well microtitre plate. The final reaction volume is 50 μL and contains a final concentra...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Portola Pharmaceuticals

US Patent
LigandPNGBDBM100350(US10533001, Example 99 | US11414410, Example 99 | ...)
Affinity DataIC50:  0.800nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50100358((S)-3-[(3-Pyridin-4-yl-3-aza-spiro[5.5]undecane-9-...)
Affinity DataIC50:  1nMAssay Description:In vitro inhibitory activity against blockage of binding of fibrinogen to purified human GPIIbIIIaMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase SYK(Homo sapiens (Human))
Portola Pharmaceuticals

US Patent
LigandPNGBDBM290819((S)-4-(3-(2H-1,2,3-triazol-2-yl)phenylamino)-2-(1-...)
Affinity DataIC50: <1nMpH: 7.5 T: 2°CAssay Description:Potency of candidate molecules for inhibiting syk tyrosine phosphorylation activity is assessed by measuring the ability of a test compound to inhibi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase SYK(Homo sapiens (Human))
Portola Pharmaceuticals

US Patent
LigandPNGBDBM50400047(BIIB-057 | CHEMBL2177736 | US9579320, Example 87)
Affinity DataIC50:  1nMAssay Description:Employing the Milipore panel of purified kinases EXAMPLE 87 (IC50=1 nM) inhibited 98% of purified Syk kinase activity at 50 nM. IC50 values were dete...More data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50100346((S)-2-(3,5-Dimethyl-isoxazole-4-sulfonylamino)-3-[...)
Affinity DataIC50:  1nMAssay Description:Inhibitory concentration of the compound against alphaV-beta3 integrinMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50092126(2-(3,5-Dimethyl-isoxazole-4-sulfonylamino)-3-[(3-p...)
Affinity DataIC50:  1nMAssay Description:In vitro inhibitory activity against blockage of binding of fibrinogen to purified human GPIIbIIIaMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50143844(3-{[2-(4-Carbamimidoyl-phenyl)-1-oxo-2,8-diaza-spi...)
Affinity DataIC50:  1nMAssay Description:Tested for inhibition of the binding of fibrinogen to purified human GPIIb-IIIa in a 96-well format (ELISA assay)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50092123(((S)-1-{2-[4-(N-Hydroxycarbamimidoyl)-benzoylamino...)
Affinity DataIC50:  1.14nMAssay Description:Tested for inhibition of the binding of fibrinogen to purified human GPIIb-IIIa in a 96-well format (ELISA assay)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50100365((S)-2-Benzyloxycarbonylamino-3-[(3-pyridin-4-yl-3-...)
Affinity DataIC50:  2nMAssay Description:In vitro inhibitory activity against blockage of binding of fibrinogen to purified human GPIIbIIIaMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50092105((S)-2-(3,5-Dimethyl-isoxazole-4-sulfonylamino)-5-o...)
Affinity DataIC50:  2nMAssay Description:Inhibition of binding of fibrinogen to purified human GPIIb-IIIa in ELISAMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50143865((S)-3-{[3-(4-Carbamimidoyl-phenyl)-1-methyl-2,4-di...)
Affinity DataIC50:  2nMAssay Description:Tested for inhibition of the binding of fibrinogen to purified human GPIIb-IIIa in a 96-well format (ELISA assay)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50111398((S)-2-(Isoxazole-4-sulfonylamino)-5-oxo-5-(2-pyrid...)
Affinity DataIC50:  2nMAssay Description:In vitro activity to block the binding of fibrinogen to purified human fibrinogen receptor.More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50100350((S)-5-Oxo-5-(9-pyridin-4-yl-3,9-diaza-spiro[5.5]un...)
Affinity DataIC50:  2nMAssay Description:Inhibitory concentration of the compound against alphaV-beta3 integrinMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50092109(3-{(S)-3-[1-(4-Carbamimidoyl-phenyl)-2-oxo-pyrroli...)
Affinity DataIC50:  2.38nMAssay Description:Tested for inhibition of the binding of fibrinogen to purified human GPIIb-IIIa in a 96-well format (ELISA assay)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPlatelet-derived growth factor receptor beta(Homo sapiens (Human))
In Vivo Sciences Millennium Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50152355(4-[3-Cyano-6-methoxy-7-(3-piperidin-1-yl-propoxy)-...)
Affinity DataIC50:  3nMAssay Description:In vitro inhibition of Platelet derived growth factor receptor beta autophosphorylation in MG-63 cells without plasmaMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50100360((S)-2-(Butane-1-sulfonylamino)-3-[(3-pyridin-4-yl-...)
Affinity DataIC50:  3nMAssay Description:In vitro inhibitory activity against blockage of binding of fibrinogen to purified human GPIIbIIIaMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Portola Pharmaceuticals

US Patent
LigandPNGBDBM100350(US10533001, Example 99 | US11414410, Example 99 | ...)
Affinity DataIC50:  3.20nM Kd:  5.10nMAssay Description:ATP-site dependent competition binding assay using Ambit KinomeScan Screening kit.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Portola Pharmaceuticals

US Patent
LigandPNGBDBM100350(US10533001, Example 99 | US11414410, Example 99 | ...)
Affinity DataIC50:  3.20nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Portola Pharmaceuticals

US Patent
LigandPNGBDBM100350(US10533001, Example 99 | US11414410, Example 99 | ...)
Affinity DataIC50:  3.20nMAssay Description:The kinase reaction is performed in a black U-bottom 96-well microtitre plate. The final reaction volume is 50 μL and contains a final concentra...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50143842(3-{[2-(4-Carbamimidoyl-phenyl)-1-oxo-2,8-diaza-spi...)
Affinity DataIC50:  3.90nMAssay Description:Tested for inhibition of the binding of fibrinogen to purified human GPIIb-IIIa in a 96-well format (ELISA assay)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50143866(3-{[2-(4-Carbamimidoyl-phenyl)-1-oxo-2,8-diaza-spi...)
Affinity DataIC50:  4nMAssay Description:Tested for inhibition of the binding of fibrinogen to purified human GPIIb-IIIa in a 96-well format (ELISA assay)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50100344((S)-2-Butoxycarbonylamino-5-oxo-5-(9-pyridin-4-yl-...)
Affinity DataIC50:  4nMAssay Description:Inhibition of binding of fibrinogen to purified human GPIIb-IIIa in ELISAMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50143872((R)-5-[2-(4-Carbamimidoyl-phenyl)-1-oxo-2,8-diaza-...)
Affinity DataIC50:  4nMAssay Description:Tested for inhibition of the binding of fibrinogen to purified human GPIIb-IIIa in a 96-well format (ELISA assay)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50143849(5-[2-(4-Carbamimidoyl-phenyl)-1-oxo-2,8-diaza-spir...)
Affinity DataIC50:  4nMAssay Description:Tested for inhibition of the binding of fibrinogen to purified human GPIIb-IIIa in a 96-well format (ELISA assay)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase SYK(Homo sapiens (Human))
Portola Pharmaceuticals

US Patent
LigandPNGBDBM50396073(CHEMBL1235110)
Affinity DataIC50:  4nMAssay Description:SYK tyrosine phosphorylation activity is measured using the LANCE Technology developed by Perkin Elmer Life and Analytical Sciences (Boston, Mass.). ...More data for this Ligand-Target Pair
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50111419(3-Oxo-3-[4-(2-pyridin-4-yl-2,8-diaza-spiro[4.5]dec...)
Affinity DataIC50:  4nMAssay Description:In vitro activity to block the binding of fibrinogen to purified human fibrinogen receptor.More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50143842(3-{[2-(4-Carbamimidoyl-phenyl)-1-oxo-2,8-diaza-spi...)
Affinity DataIC50:  4nMAssay Description:Tested for inhibition of the binding of fibrinogen to purified human GPIIb-IIIa in a 96-well format (ELISA assay)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPlatelet-derived growth factor receptor beta(Homo sapiens (Human))
In Vivo Sciences Millennium Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50152344(4-[6-Methoxy-7-(3-morpholin-4-yl-propoxy)-quinazol...)
Affinity DataIC50:  5nMAssay Description:In vitro inhibition of Platelet derived growth factor receptor beta autophosphorylation in MG-63 cells without plasmaMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPlatelet-derived growth factor receptor beta(Homo sapiens (Human))
In Vivo Sciences Millennium Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50152358(4-[6-Methoxy-7-(2-pyrrolidin-1-yl-ethoxy)-quinazol...)
Affinity DataIC50:  5nMAssay Description:In vitro inhibition of Platelet derived growth factor receptor beta autophosphorylation in MG-63 cells without plasmaMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50143840((S)-5-[2-(4-Carbamimidoyl-phenyl)-1-oxo-2,8-diaza-...)
Affinity DataIC50:  5nMAssay Description:Tested for inhibition of the binding of fibrinogen to purified human GPIIb-IIIa in a 96-well format (ELISA assay)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50143874((R)-3-{[2-(4-Carbamimidoyl-phenyl)-1-oxo-2,8-diaza...)
Affinity DataIC50:  5nMAssay Description:Tested for inhibition of the binding of fibrinogen to purified human GPIIb-IIIa in a 96-well format (ELISA assay)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPlatelet-derived growth factor receptor beta(Homo sapiens (Human))
In Vivo Sciences Millennium Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50152361(4-[3-Cyano-6-methoxy-7-(3-piperidin-1-yl-propoxy)-...)
Affinity DataIC50:  5nMAssay Description:In vitro inhibition of Platelet derived growth factor receptor beta autophosphorylation in MG-63 cells without plasmaMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50143850(2-Butoxycarbonylamino-5-[2-(4-carbamimidoyl-phenyl...)
Affinity DataIC50:  5nMAssay Description:Tested for inhibition of the binding of fibrinogen to purified human GPIIb-IIIa in a 96-well format (ELISA assay)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-IIb/beta-3(Homo sapiens (Human))
Cor Therapeutics

Curated by ChEMBL
LigandPNGBDBM50143864(5-[2-(4-Carbamimidoyl-phenyl)-1-oxo-2,8-diaza-spir...)
Affinity DataIC50:  5nMAssay Description:Tested for inhibition of the binding of fibrinogen to purified human GPIIb-IIIa in a 96-well format (ELISA assay)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase SYK(Homo sapiens (Human))
Portola Pharmaceuticals

US Patent
LigandPNGBDBM291000((R)-2-(2-amino-3-methoxypropylamino)-4-(2-methyl-2...)
Affinity DataIC50:  5.5nMpH: 7.5 T: 2°CAssay Description:Potency of candidate molecules for inhibiting syk tyrosine phosphorylation activity is assessed by measuring the ability of a test compound to inhibi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase SYK(Homo sapiens (Human))
Portola Pharmaceuticals

US Patent
LigandPNGBDBM291001((R)-2-(2-amino-3-methoxypropylamino)-4-(2,3-dihydr...)
Affinity DataIC50:  5.5nMpH: 7.5 T: 2°CAssay Description:Potency of candidate molecules for inhibiting syk tyrosine phosphorylation activity is assessed by measuring the ability of a test compound to inhibi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase SYK(Homo sapiens (Human))
Portola Pharmaceuticals

US Patent
LigandPNGBDBM291019((R)-2-(1-aminobutan-2-ylamino)-4-(3-(2H-1,2,3-tria...)
Affinity DataIC50:  5.5nMpH: 7.5 T: 2°CAssay Description:Potency of candidate molecules for inhibiting syk tyrosine phosphorylation activity is assessed by measuring the ability of a test compound to inhibi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase SYK(Homo sapiens (Human))
Portola Pharmaceuticals

US Patent
LigandPNGBDBM291025((S)-2-(2-aminobutylamino)-4-(1-ethyl-1H-indol-4-yl...)
Affinity DataIC50:  5.5nMpH: 7.5 T: 2°CAssay Description:Potency of candidate molecules for inhibiting syk tyrosine phosphorylation activity is assessed by measuring the ability of a test compound to inhibi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase SYK(Homo sapiens (Human))
Portola Pharmaceuticals

US Patent
LigandPNGBDBM291026((S)-2-(2-amino-2-cyclopropylethylamino)-4-(1-methy...)
Affinity DataIC50:  5.5nMpH: 7.5 T: 2°CAssay Description:Potency of candidate molecules for inhibiting syk tyrosine phosphorylation activity is assessed by measuring the ability of a test compound to inhibi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase SYK(Homo sapiens (Human))
Portola Pharmaceuticals

US Patent
LigandPNGBDBM291027((S)-2-(2-aminobutylamino)-4-(1-methyl-1H-indol-4-y...)
Affinity DataIC50:  5.5nMpH: 7.5 T: 2°CAssay Description:Potency of candidate molecules for inhibiting syk tyrosine phosphorylation activity is assessed by measuring the ability of a test compound to inhibi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase SYK(Homo sapiens (Human))
Portola Pharmaceuticals

US Patent
LigandPNGBDBM291028((R)-2-(2-amino-3-ethoxypropylamino)-4-(1-ethyl-1H-...)
Affinity DataIC50:  5.5nMpH: 7.5 T: 2°CAssay Description:Potency of candidate molecules for inhibiting syk tyrosine phosphorylation activity is assessed by measuring the ability of a test compound to inhibi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase SYK(Homo sapiens (Human))
Portola Pharmaceuticals

US Patent
LigandPNGBDBM291029((R)-2-(2-amino-3-methoxypropylamino)-4-(1H-indol-4...)
Affinity DataIC50:  5.5nMpH: 7.5 T: 2°CAssay Description:Potency of candidate molecules for inhibiting syk tyrosine phosphorylation activity is assessed by measuring the ability of a test compound to inhibi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase SYK(Homo sapiens (Human))
Portola Pharmaceuticals

US Patent
LigandPNGBDBM365380(US10533001, Example 41 | US11414410, Example 41 | ...)
Affinity DataIC50:  5.5nMAssay Description:Syk and JAK: The activity of a specified compound as an inhibitor of a JAK kinase may be assessed in vitro or in vivo. In some embodiments, the activ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase SYK(Homo sapiens (Human))
Portola Pharmaceuticals

US Patent
LigandPNGBDBM365380(US10533001, Example 41 | US11414410, Example 41 | ...)
Affinity DataIC50:  5.5nMAssay Description:The kinase reaction is performed in a black U-bottom 96-well microtitre plate. The final reaction volume is 50 μL and contains a final concentra...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase SYK(Homo sapiens (Human))
Portola Pharmaceuticals

US Patent
LigandPNGBDBM290627(2-((1R,2S)-2-aminocyclohexylamino)-4-(3-(pyridin-3...)
Affinity DataIC50:  5.5nMpH: 7.5 T: 2°CAssay Description:Potency of candidate molecules for inhibiting syk tyrosine phosphorylation activity is assessed by measuring the ability of a test compound to inhibi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase SYK(Homo sapiens (Human))
Portola Pharmaceuticals

US Patent
LigandPNGBDBM290641(4-(3-(1H-pyrazol-1-yl)phenylamino)-2-((1R,2S)-2-am...)
Affinity DataIC50:  5.5nMpH: 7.5 T: 2°CAssay Description:Potency of candidate molecules for inhibiting syk tyrosine phosphorylation activity is assessed by measuring the ability of a test compound to inhibi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase SYK(Homo sapiens (Human))
Portola Pharmaceuticals

US Patent
LigandPNGBDBM290647(2-((1R,2S)-2-aminocyclohexylamino)-4-(3-(thiazol-4...)
Affinity DataIC50:  5.5nMpH: 7.5 T: 2°CAssay Description:Potency of candidate molecules for inhibiting syk tyrosine phosphorylation activity is assessed by measuring the ability of a test compound to inhibi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase SYK(Homo sapiens (Human))
Portola Pharmaceuticals

US Patent
LigandPNGBDBM290649(2-((1R,2S)-2-aminocyclohexylamino)-4-(3-(thiazol-2...)
Affinity DataIC50:  5.5nMpH: 7.5 T: 2°CAssay Description:Potency of candidate molecules for inhibiting syk tyrosine phosphorylation activity is assessed by measuring the ability of a test compound to inhibi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 1333 total ) | Next | Last >>
Jump to: